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a  b  s  t  r  a  c  t
Follicular  lymphoma  (FL) is a heterogeneous  disease  with  some  patients  developing  progressively  or
transformed  disease  early,  whereas  others  follow  an  indolent  clinical  course.  We  evaluated  the  prognostic
value of immunoglobulin  heavy  chain  variable  (IGHV)  gene  usage  and  mutational  status  in  FL  patients.
One  hundred  and  four  IGH sequences  were  obtained  in  tumour  samples  from  99 patients.  The  IGHV3
subgroup  had  the highest  usage  frequency  (57.7%)  with  IGHV3–23  being  the  most  common  sequence.
Patients  with  the  IGHV5  subgroup  or IGHV  sequences  from  more  than  one  subgroup  had  signiﬁcantly  less
favourable  prognosis  with  an  estimated  5-year  survival  of  62.5  and  50.0%,  respectively,  as  compared  with
a 5-year  survival  of  95.1%  for patients  with  other  IGHV  subgroups  (P  = 0.013  and  P < 0.001,  log–rank).  The
poor  survival  associated  with  IGHV5  or >1  IGHV  subgroup  usage  was  an  independent  prognostic  factoromatic hypermutations
rognosis
in Cox  multivariate  analysis  (P = 0.005).  IGHV  genes  were  unmutated  showing  >98% homology  in  15.2%
of  cases.  Contrasting  the  situation  in  chronic  lymphocytic  leukaemia  (CLL),  the  presence  of  unmutated
sequences  did  not  yield  prognostic  information,  although  unmutated  sequences  were  associated  with
age at  diagnosis  >60  years  (P = 0.022,  Fisher’s  exact).  In conclusion,  our  results  indicate  that  analysis  of
IGHV gene  usage  might  aid  in  predicting  prognosis  for FL  patients.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Follicular lymphoma (FL) is the second most common B cell
ymphoma after diffuse large B cell lymphoma (DLBCL) in West-
rn countries [1]. FL is clinically characterised by a median survival
f more than 10 years and a continuous pattern of relapse that
ften is associated with progression to treatment-resistant dis-
ase and sometimes is associated with histological transformation
nto DLBCL [2,3]. The translocation t(14;18)(q32;q21) deregulating
CL2 expression is considered the primary oncogenic event, but
s also considered insufﬁcient for FL development due to the fre-
uent occurrence of this translocation in B cells of healthy human
ndividuals [4–6].
∗ Corresponding author at: Department of Pathology, Haukeland University Hos-
ital, 5021 Bergen, Norway. Tel.: +47 55 97 31 64; fax: +47 55 97 31 58.
E-mail addresses: ellen.berget@gades.uib.no (E. Berget),
nders.molven@gades.uib.no (A. Molven), turid.lokeland@helse-bergen.no
T. Løkeland), lars.helgeland@helse-bergen.no (L. Helgeland),
lav.vintermyr@helse-bergen.no (O.K. Vintermyr).
ttp://dx.doi.org/10.1016/j.leukres.2015.03.003
145-2126/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unIt has long been assumed that FL is derived from the malig-
nant transformation of germinal centre B cells. Morphologically,
FLs are composed of tumour cells that appear in a predominantly
follicular pattern with cytological and architectural features of nor-
mal  germinal centres, and that usually express germinal centre B
cells’ markers such as BCL6 and CD10 [7]. The germinal centre B
cell origin has been supported by several previous studies of the
immunoglobulin heavy variable (IGHV) and light chain genes demon-
strating heavily mutated genes [8–12]. In comparison to normal
germinal centre B cells, FLs contain signiﬁcantly more mutations in
the IGHV genes, an observation compatible with prolonged expan-
sion in a germinal centre-like environment [12,13].
The analysis of IGHV genes of other B cell lymphomas, including
chronic lymphocytic leukaemia (CLL), splenic marginal zone
lymphoma (SMZL) and mantle cell lymphoma (MCL) has revealed
an unexpected heterogeneity in mutational status [14–18]. This
heterogeneity has also been related to prognosis particularly in
CLL, in which IGHV sequence analysis now has become widely
used for the purpose of prognostication [19,20]. Furthermore,
the increasing use of IGHV sequence analysis in CLL patients has
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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llowed the recognition of speciﬁc IGHV genes that are associated
ith unfavourable prognosis, such as the IGHV3–21 gene [21–24].
Although most studies have shown that FL is characterised by
utated IGHV genes [8–12], a recent investigation has revealed that
nmutated genes could also be present in FL [25]. Moreover, there
ave been only occasional reports on the distribution of IGHV sub-
ypes in FL [8,10,12,26], and to our knowledge there has been no
tudy attempting to correlate IGHV sequence analysis with clinical
utcome. In the present study, the aim was, therefore, to analyse
he use of IGHV genes and mutational status in relation to clinico-
athological characteristics and prognosis in FL.
. Materials and methods
.1. Patients
The 106 patients included in the study had FL grade 1–3B at time of diagno-
is,  and all had a bone marrow biopsy evaluated for lymphoma involvement at
he Department of Pathology, Haukeland University Hospital, Bergen, Norway in
he period between February 2003 and July 2011. Patients with transformed FL at
iagnosis were excluded. Bone marrow status for 96 cases was reported previously
27]. Diagnoses according to the WHO  classiﬁcation were based on morphological
nd immunohistochemical assessment of formalin-ﬁxed, parafﬁn-embedded (FFPE)
umour biopsies from lymph nodes and extranodal sites [7]. Medical records were
eviewed to determine age, sex, clinical stage, follicular lymphoma international
rognostic index (FLIPI) score, management and disease course. FLIPI score was  also
etermined for the patients with 3B FL, although clinically regarded as equivalent
o  the diagnosis of DLBCL. The study was approved by the Regional Committee for
thics in Research (2013/211) and performed in accordance with the Declaration of
elsinki.
.2. PCR ampliﬁcation and sequencing
DNA was  prepared from FFPE tumour material. In most cases, two 10 m sec-
ions were cut from the parafﬁn blocks and deparafﬁnised with Deparafﬁnisation
olution (Qiagen, Hilden, Germany). In one case, tumour material was successfully
issected from a haematoxylin and eosin stained slide before deparafﬁnisation.
utomated DNA isolation was  performed on a QIAsymphony SP pipetting robot (Qia-
en) in combination with the QIAsymphony DSP DNA Mini Kit (Qiagen) according
o  the manufacturer’s instructions.
PCR was performed in six separate reactions with the IGH framework region 1
FR1) primers combined with the JH consensus primer as designed for the BIOMED-
 protocol [28]. The BIOMED-2 procedure was  adapted for FFPE tissue by using the
IAGEN Multiplex PCR Kit (Qiagen) with HotStarTaq DNA Polymerase as previously
escribed [29]. All reactions were carried out in a total reaction volume of 25 l con-
aining 2.5 l of DNA template, 2.5 l of primer mix  (2 M of each primer), 12.5 l of
he  Multiplex buffer and 7.5 l ddH2O. PCR conditions included an initial activation
tep (95 ◦C, 15 min), 38 cycles consisting of denaturation (95 ◦C, 45 s), annealing of
CR primers (60 ◦C, 90 s) and extension (72 ◦C, 90 s), and a ﬁnal extension step of
2 ◦C for 10 min. PCR products were analysed on a 3% agarose gel, visualised with
thidium bromide staining and PCR reactions that showed bands of appropriate size
able 1
linicopathological variables and results from univariate survival analysis in the 106 pati
Variables N % HR
Sex
Female 64 60.4 1
Male 42 39.6 1.0
Age  (years)
≤60 46 43.4 1
>60 60 56.6 3.8
Morphology
Grades  1/2 77 72.6 1
Grades 3A/3B 29 27.4 0.6
Bone  marrow
No involvement 73 68.9 1
Involvement 33 31.1 1.0
Clinical  stage
I-II 34 32.1 1
III-IV 72 67.9 1.4
FLIPI  score
Low (0–1) 49 46.2 1
Intermediate (2) 26 24.5 2.7
High  (≥3) 31 29.3 5.4
R, hazard ratio; CI, conﬁdence interval; FLIPI, follicular lymphoma international prognoarch 39 (2015) 702–708 703
were identiﬁed. If several appropriate bands were present in a case, each of the pos-
itive PCR reactions was  selected for sequencing. For each case, a multiplexed PCR
reaction consisting of the six IGH FR1 primers and the JH consensus primer was
also  performed. The multiplexed PCR reaction served as an internal control for the
presence of clonal rearrangements.
In preparation for sequencing, the IllustraTM ExoProStarTM 1-Step Kit (GE
Healthcare, Little Chalfont Buckinghamshire, UK) was  used in order to remove
unincorporated primers and nucleotides from the ampliﬁcation reactions. Direct
sequencing was  performed in both directions using the same primers as in the
PCR ampliﬁcation and the BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Foster City, California, USA). Sequencing reactions were puriﬁed by the
BigDye®  XTerminatorTM Puriﬁcation Kit and subsequently analysed on an ABI Prism
3100 Genetic Analyser (both Applied Biosystems).
Sequence data analysis was done using CLC Main Workbench software (Qia-
gen). DNA sequence reads were automatically trimmed based on quality scores
(0.05 limit) and ambiguity characters (two residues). Manual trimming was per-
formed in a minority of the cases (n = 4). When DNA sequence reads from both
directions were obtained, they were assembled to contigs (73 sequences). Conﬂicts,
i.e. disagreements about residues in a position, were solved by letting the read with
best  quality decide the nucleotide in the contig. Contigs and single DNA sequence
reads were aligned to the closest IGH sequences derived from the IMGT database
(http://www.imgt.org/IMGT vquest/vquest) and the percentage of homology deter-
mined.
2.3. Statistical analysis
To compare categorical variables 2 or Fisher’s exact tests were performed. Con-
tinuous variables not following the normal distribution were compared between
two or more groups using the Mann–Whitney U or Kruskal–Wallis tests. Survival
curves of time to death due to lymphoma were estimated using the product-limit
procedure (Kaplan–Meier method) with date of histological diagnosis as start-
ing point. Differences between categories were estimated by the log–rank test.
Patients who died of other causes than lymphoma were treated as censored observa-
tions. Median follow-up time was estimated by the reversed Kaplan–Meier method.
Univariate and multivariate analyses of survival were performed with the Cox
proportional hazards method. The variables were tested by log–log plot and no
non-proportionality was found. To determine their ability to be incorporated in
multivariate models, the variables were tested by forward and backward stepwise
selection. All results were considered signiﬁcant if P≤0.05. SPSS version 21.0 (SPSS
Inc, Chicago, IL, USA) was used for all statistical analyses.
3. Results
3.1. Clinical and pathological characteristics
There were 106 patients included with ages ranging from 33
to 94 years (median 61 years). Sixty (56.6%) patients were initially
treated with cyclophosphamide, doxorubicin, vincristine and pred-
nisolon (CHOP) or COP. In these patients, Rituximab was added
in 55 and radiation therapy was applied as consolidation in 16.
There were four patients with grade 3B FL, and all four were
ents.
 95% CI P value (log–rank test)
92 0.326–3.662 0.886
23 0.837–17.463 0.063
78 0.317–1.451 0.305
14 0.304–3.385 0.982
65 0.877–2.447 0.109
23 0.455–16.318 0.266
92 1.139–26.476 0.016
stic index.
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Table 2
Cases of follicular lymphoma with more than one productive IGH rearranged sequence.
Closest VDJ gene segments
Case V D J Homology with the closest IGHV gene (%)
3 V3–23 D5–24 J4 91.0
V5–51 D3–22 J4 93.6
7  V1–46 D6–06 J6 98.8
V3–48 D4–23 J3 74.2
61  V1–24 D1–26 J2 94.8
V3–23 D2–02 J4 99.5
a
p
u
I
a
f
u
d
a
s
3
w
(
o
e
(
t
f
o
(
d
I
F
oV4–59 D3–03 
90  V3–23 D6–06 
V5–51 D6–25 
mong the patients treated with CHOP or R-CHOP. Thirteen (12.3%)
atients received chlorambucil. One patient (0.9%) received Rit-
ximab monotherapy. Seventeen (16.0%) patients with stage I or
I and grade 1 or 2 FL, were treated with local radiation ther-
py. Fifteen (14.2%) patients underwent observation only. Median
ollow-up time was 75 months (range, 62–88). During the follow-
p period, 12 patients died as a consequence of their lymphoma
isease and eight died of other causes. Clinicopathological char-
cteristics with results from univariate analysis of survival are
ummarised in Table 1.
.2. IGHV, IGHD and IGHJ usage
One hundred and four productive IGH rearranged sequences
ere obtained in samples from 99 patients. Double (n = 3) or triple
n = 1) productive IGH rearranged sequences were obtained in four
f these patients (Table 2).
Among the 25 functional IGHV genes used, the most frequently
ncountered were IGHV3–23 (12.5%), IGHV3–48 (11.5%), IGHV3–15
8.7%), IGHV4–59 (7.7%) and IGHV5–51 (6.7%, Fig. 1). The use of
hese speciﬁc genes was not correlated with prognosis. The most
requently encountered IGHV genes in the cases with more than
ne productive sequence were IGHV3–23 (n = 3) and IGHV5–51
n = 2, Table 2). The frequencies of IGHV subgroups in the 104 pro-
uctive sequences had the following distribution: IGHV1, 19.2%;
GHV3, 57.7%; IGHV4, 11.5%; IGHV5, 7.7% and IGHV6, 3.8%. The
ig. 1. Usage frequency of IGHV genes in follicular lymphoma. Along the X-axis are sh
btained from 99 patients.J3 89.8
J5 86.8
J4 100.0
IGHV2 subgroup was not observed in any of the sequences. Twenty
three different functional IGHD genes were used. The most fre-
quently encountered were IGHD3–10 (8.7%), IGHD3-03 (7.7%) and
IGHD3–22 (6.7%). The most frequently expressed IGHJ genes were
IGHJ4 (51.0%), IGHJ6 (21.2%) and IGHJ3 (17.3%).
No productive IGHV-D-J rearrangements could be obtained
in the remaining seven patients. In three of these cases, we
were unable to establish clonality by the BIOMED-2 framework
region one, two and three primers, probably due to the technical
limitations related to use of FFPE tissue. Four cases had no mate-
rial (FFPE tissue or DNA) left after routine diagnostic work was
completed.
3.3. IGHV mutation status
The percentage of homology to the closest IGHV gene ranged
from 60.4% to 100.0%, with a mean of 89.4% for the 104 productive
sequences.
The means for the IGHV subgroups were: IGHV1, 95.4%; IGHV3,
88.1%; IGHV4, 86.3%; IGHV5, 91.3% and IGHV6, 87.0% (Fig. 2).
A Kruskal–Wallis test revealed a statistically signiﬁcant differ-
ence in IGHV sequence homology levels across the different
IGHV subgroups (P < 0.001). The IGHV1 subgroup recorded the
highest median score (95.3%), while the IGHV4 subgroup had
the lowest (86.6%). Additional testing of the median values
with Mann–Whitney U test with Bonferroni adjustment showed
own the 25 different IGHV sequences detected among 104 productive sequences
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Tig. 2. Homology of IGHV genes in follicular lymphoma. The diagram shows perce
rom  99 patients. Each observation is indicated by a dot and horizontal lines repres
igniﬁcant differences between IGHV1 and IGHV3, and between
GHV1 and IGHV4 (both P < 0.001).
Fifteen productive sequences were unmutated, deﬁned as >98%
omology to the closest IGHV gene. Three of these sequences
howed 100% homology. Unmutated sequences were observed in
he IGHV1, IGHV3, IGHV5 and IGHV6 subgroups. IGHV1 subgroup
xhibited the highest number of unmutated sequences. When com-
ared with the IGHV3 and the IGHV4 subgroup, the difference was
tatistically signiﬁcant (P = 0.004 and P = 0.029, Fisher’s exact test).
.4. Correlation of IGHV subgroup usage with clinical outcome
The estimated survival at 5 years was 62.5% (SE 21.3%) for
atients displaying the IGHV5 subgroup and 50.0% (SE 25.0%) for
atients exhibiting more than one IGHV subgroup, whereas the
stimated survival for patients using the other IGHV subgroups
ombined was 95.1% (SE 2.4%). Patients using IGHV5 or more than
ne IGHV subgroup had a signiﬁcantly poorer survival by log–rank
est (P = 0.013 and P < 0.001, respectively) as compared to patients
sing other IGHV subgroups. When the patients using the IGHV5 and
able 3
nivariate survival analysis of IGHV subgroup usage and mutation status according to dif
Variables N HR 
IGHV subgroup
IGHV1-4, IGHV6 89 1
IGHV5 or >1 IGHV 10 7.555 
IGHV homology
≤93% 69 1
>93% 30 2.589 
IGHV  homology
≤96% 81 1
>96% 18 2.198 
IGHV  homology
≤98% 84 1
>98% 15 1.824 
IGHV  homology
≤99% 89 1
>99% 10 1.617 
R, hazard ratio; CI, conﬁdence interval.
he sequences with the highest homology score were included in patients with double or of homology according to IGHV subgroups in 104 productive sequences obtained
ean percentage of homology for the IGHV subgroup.
more than one IGHV subgroup were combined in a single group esti-
mated hazard ratio was  7.6 (95% CI, 2.1–26.9, Table 3) with P < 0.001
by log–rank test (Fig. 3). Supplementary t(14;18)(q32;q21) ﬂuores-
cence in situ hybridisation analysis (BCL2) and PCR (BCL2 MBR  and
MCR) was  performed in 10 cases with IGHV5 or >1 IGHV subgroup
expression. BCL2 translocation was  detected in eight supporting the
diagnosis of follicular lymphoma (data not shown).
Usage of IGHV5 was associated with age >60 years at diagnosis,
whereas usage of more than one IGHV subgroup was not (Supple-
mentary Table S1). Usage of IGHV5 or more than one IGHV subgroup
was not associated with FL grade 3A/3B, clinical stage >III/IV or
FLIPI score ≥3. Furthermore, no correlation between usage of IGHD
or IGHJ genes and clinicopathological variables including patient’s
survival was detected.
3.5. Correlation of IGHV mutation status with clinicopathological
variables
Unmutated IGHV sequences with >98% homology to the closest
IGHV gene was observed more frequently in patients with age >60
ferent homology cutoff values in the 99 patients with productive rearrangements.
95% CI P value (log–rank test)
2.119–26.931 <0.001
0.827–8.108 0.090
0.661–7.307 0.187
0.493–6.743 0.360
0.353–7.396 0.532
 triple productive IGH rearranged sequences.
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Fig. 3. Survival of follicular lymphoma patients according to IGHV subgroup usage. Kaplan–Meier survival curves of 99 patients are shown. The survival of patients using
t into a single group, and compared to the survival of patients using the IGHV1–4 or IGHV6
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Table 4
Cox multivariate analysis of prognostic factors in the 99 patients with productive
IGH  rearranged sequences.
Variables HR 95% CI P value
Age >60 years 2.830 0.614–13.033 0.182
Clinical stages III/IV 4.143 0.447–38.398 0.211
FLIPI score ≥3 1.942 0.535–7.042 0.313
IGHV5 or >1 IGHV subgroup 5.621 1.484–21.290 0.005
IGHV homology >93% 2.185 0.630–7.571 0.218he  IGHV5 subgroup (n = 6) or more than one IGHV subgroup (n = 4) were combined 
ubgroups. Statistical difference was calculated by the log-rank test.
ears (13 of 58 patients; 22.4%) than in patients aged ≤60 years (two
f 41 patients; 4.9%), when sequences with the highest homology
cores were included for the patients with double or triple pro-
uctive rearranged IGH sequences. The difference was  statistically
igniﬁcant by Fisher’s exact test (P = 0.022). Unmutated sequences
ere associated with >1 IGHV subgroup usage, but not with IGHV5
ubgroup usage (Supplementary Table S1). There were no signif-
cant associations between unmutated IGHV genes and the other
linicopathological variables studied.
The estimated survival at 5 years was 80.0% (SE 10.3%) for
atients carrying unmutated IGHV genes and 93.6% (SE 2.8%) for
atients with mutated IGHV. The difference in survival was not
igniﬁcant by log–rank test. Moreover, no signiﬁcant impact on
urvival was observed according to different homology cutoff val-
es (Table 3). The estimated hazard ratio was 2.6 (95% CI, 0.8–8.1,
 = 0.090) when a cutoff of >93% homology was used.
.6. Multivariate survival analysis
The combination of IGHV5 and >1 IGHV subgroup usage
emained a signiﬁcant factor in a multivariate analysis when the
ariables age >60 years, clinical stage >III/IV, FLIPI score ≥3 and
GHV homology >93% were included (Table 4).
. DiscussionOur analysis showed that the usage of IGHV genes used in
ollicular lymphomas mostly resembled the repertoire of normal
eripheral blood B cells [30,31]. Thus, the IGHV3–23 gene was the
ost frequently used IGHV gene. However, some discrepanciesHR, hazard ratio; CI, conﬁdence interval; FLIPI, follicular lymphoma international
prognostic index.
were observed. The IGHV3–15, IGHV3–48 and the IGHV5–51 genes,
which are not among the most frequently employed IGHV genes
in normal B cells, were frequently expressed in our patient cohort.
Conversely, the IGHV3-30-3 and the IGHV4–39 genes that are
common in normal B cells were not represented in our patients.
The IGHV3–23 was the most frequently used gene also in a previ-
ous study of 30 FL samples [12]. In that study, however, IGHV3–15,
IGHV3–48 and IGHV5–51 were not commonly expressed, con-
trasting our results. In another study of 26 FLs, the IGHV1–18 and
the IGHV3–48 were the most frequently encountered genes [32].
Although relative frequencies of individual IGHV genes diverge
among series, the frequencies of IGHV subgroups tend to be more
similar for FL [8,12,26,32,33]. In agreement with previous studies,
IGHV3 was  the most frequently used subgroup, followed by the
IGHV1 and IGHV4 subgroups.A novel ﬁnding in our study was that usage of IGHV subgroups
was related to survival. Unfavourable prognosis was observed for
two patient groups; the patients using the IGHV5 subgroup and
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he patients using more than one IGHV subgroup. Whether these
atient groups were compared separately or combined, survival
as signiﬁcantly different from that of patients using other IGHV
ubgroups. The poor survival associated with subgroup usage was
lso of independent prognostic importance in a multivariate model.
imilarly, the IGHV3–21 gene has been correlated with poor clin-
cal outcome in studies of CLL [21,22]. The IGHV3–21 gene was
xpressed in only two of our FL patients, and an association with
rognosis could; therefore, not be evaluated. Other IGHV genes
r subgroups have, to our knowledge, not been associated with
dverse prognosis, neither in CLL nor in other B cell neoplasms.
The IGHV genes were commonly mutated in our study, as
lso observed in previous studies of FL [10,12,32,34]. Unexpect-
dly, however, unmutated IGHV genes were detected in 15.2%
15/99) of the patients from whom productive rearrangements
ere obtained. Three of these patients even had truly unmu-
ated IGHV genes showing 100% homology. Unmutated IGHV genes
ave previously been observed in a minority of other germinal or
ost-germinal centre-associated lymphomas, such as DLBCL and
urkitt lymphoma [35–39], but to our knowledge not in FL. Due
o the unexpected high frequency of unmutated IGHV genes in
ur patients, the morphology of these cases were re-evaluated.
orphological and immunophenotypic characteristics of FL were
onﬁrmed in all cases. Nine showed FL grades one and two, ﬁve
rades 3A and one grade 3B.
We  were unable to show any signiﬁcant difference in survival for
atients carrying unmutated IGHV genes as compared with patients
arrying mutated sequences, despite the fact that unmutated IGHV
enes were seen more frequently in patients with age >60 years.
he reason for the association with age is unclear. The 98% homol-
gy cutoff value for assigning cases to the unmutated or mutated
ubgroup has been widely used for prognostication in CLL. Recently,
he best cutoff identity of IGHV genes to predict survival was  shown
o be 97% in MCL  [40]. Cutoffs of 98 or 97% may  not necessarily be
ppropriate for FL. We  were, however, not able to detect any signif-
cant differences in survival according to different homology cutoff
alues in our FL patients (Table 3).
Although no differences in outcome were detected, the observa-
ion of unmutated and truly unmutated IGHV genes indicates that
 subset of FL cases could be derived from pre-germinal centre B
ells. A more naïve cell of origin has previously also been suggested
or the unmutated cases of CLL and MCL. [15,40] On the other hand,
utational status appeared to be related to the use of different IGHV
ubgroups with the IGHV1 subgroup showing highest number of
nmutated sequences. Such biased IGHV usage could also reﬂect
election and activation by a restricted set of antigens, superanti-
ens, or both [41]. Accordingly, the deﬁnition of a cell of origin
or a subset of FL cases may  be facing the same challenges already
ncountered for CLL [42].
We  also observed a somewhat higher frequency of IGHV5 sub-
roup usage in our FLs (7.7%) than that reported for normal
eripheral blood B cells, i.e. 1.4% for CD5+ and 2.9% for CD5− B
ells [30]. These differences suggest an overrepresentation of IGHV5
enes in FL. Given the poorer survival of IGHV5-positive patients, it
s tempting to speculate that speciﬁc antigens may  be responsible
or a more aggressive clinical course in this subset of FL patients.
In summary, the IGHV3 subgroup and in particular the IGHV3–23
ere the most frequently used in FL. Usage of the IGHV5 and more
han one IGHV subgroup were associated with shorter survival, and
as an independent risk factor in multivariate analysis. Although
alidation in larger series is warranted, the survival data indicate
hat IGHV sequence analysis could aid in predicting prognosis of
L patients. Finally, heterogeneity in mutational status was  noted
s also unmutated IGHV genes were present. This could raise the
ossibility that a subset of FLs might be derived from pre-germinal
entre B cells.
[
[arch 39 (2015) 702–708 707
Conﬂicts of interest statement
There are no conﬂicts of interest to declare.
Acknowledgements
The study has been funded by a fellowship from the University
of Bergen, and grants provided by the Western Norway Regional
Health Authority and Dr. Med  F. G. Gades Legat.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/j.leukres.
2015.03.003.
References
[1] Roman E, Smith AG. Epidemiology of lymphomas. Histopathology
2011;58(1):4–14.
[2] Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international
prognostic index. Blood 2004;104(5):1258–65.
[3] Federico M,  Bellei M,  Marcheselli L, et al. Follicular lymphoma international
prognostic index 2: a new prognostic index for follicular lymphoma developed
by the international follicular lymphoma prognostic factor project. J Clin Oncol
2009;27(27):4555–62.
[4] Liu YF, Hernandez AM, Shibata D, et al. BCL2 translocation frequency rises with
age  in humans. Proc Natl Acad Sci USA 1994;91(19):8910–4.
[5] Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in
blood B cells of normal individuals. Blood 1995;85(9):2528–36.
[6] Dolken G, Illerhaus G, Hirt C, et al. BCL-2/J(H) rearrangements in circulating B
cells of healthy blood donors and patients with nonmalignant diseases. J Clin
Oncol 1996;14(4):1333–44.
[7] Swerdlow SH, Campo E, Harris NL, et al., editors. WHO  classiﬁcation of tumours
of  haematopoietic and lymphoid tissues. 4th ed Lyon: IARC Press; 2008.
[8] Bahler DW,  Campbell MJ,  Hart S, et al. Ig VH gene expression among human
follicular lymphoma. Blood 1991;78(6):1561–8.
[9] Zhu D, Hawkins RE, Hamblin TJ, et al. Clonal history of a human follicular lym-
phoma as revealed in the immunoglobulin variable region genes. Br J Haematol
1994;86(3):505–12.
10] Stamatopoulos K, Kosmas C, Papadaki T, et al. Follicular lymphoma
immunoglobulin kappa light chains are affected by the antigen selection pro-
cess, but to a lesser degree than their partner heavy chains. Br J Haematol
1997;96(1):132–46.
11] Ottensmeier Ch, Fau-Thompsett AR, Thompsett Ar, Fau-Zhu D, Zhu D, Fau-
Wilkins BS, et al. Analysis of VH genes in follicular and diffuse lymphoma shows
ongoing somatic mutation and multiple isotype transcripts in early diseases
with changes during disease progression. Blood 1998;91(11):4292–9.
12] Aarts WM,  Bende RJ, Steenbergen EJ, et al. Variable heavy chain gene analysis
of follicular lymphomas: correlation between heavy chain isotype expression
and somatic mutation load. Blood 2000;95(9):2922–9.
13] Pascual V, Liu YJ, Magalski A, et al. Analysis of somatic mutation in ﬁve B cell
subsets of human tonsil. J Exp Med  1994;180(1):329–39.
14] Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expres-
sion as novel prognostic indicators in chronic lymphocytic leukemia. Blood
1999;94(6):1840–7.
15] Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are asso-
ciated with a more aggressive form of chronic lymphocytic leukemia. Blood
1999;94(6):1848–54.
16] Algara P, Mateo MS, Sanchez-Beato M,  et al. Analysis of the IgV(H) somatic
mutations in splenic marginal zone lymphoma deﬁnes a group of unmu-
tated cases with frequent 7q deletion and adverse clinical course. Blood
2002;99(4):1299–304.
17] Bahler DW,  Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas
appear to originate from different B cell types. Am J Pathol 2002;161(1):81–8.
18] Camacho FI, Algara P, Rodriguez A, et al. Molecular heterogeneity in MCL
deﬁned by the use of speciﬁc VH genes and the frequency of somatic mutations.
Blood 2003;101(10):4042–6.
19] Ghia P, Stamatopoulos K, Belessi C, et al. ERIC recommendations on IGHV
gene mutational status analysis in chronic lymphocytic leukemia. Leukemia
2007;21(1):1–3.
20] Langerak AW,  Davi F, Ghia P, et al. Immunoglobulin sequence analysis and
prognostication in CLL: guidelines from the ERIC review board for reliable
interpretation of problematic cases. Leukemia 2011;25(6):979–84.21] Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3–21
genes characterize a new subset of chronic lymphocytic leukemia. Blood
2002;99(6):2262–4.
22] Thorselius M, Krober A, Murray F, et al. Strikingly homologous immunoglob-
ulin gene rearrangements and poor outcome in V(H)3–21-using chronic
7 a Rese
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[08 E. Berget et al. / Leukemi
lymphocytic leukemia patients independent of geographic origin and muta-
tional status. Blood 2006;107(7):2889–94.
23] Bomben R, Dal Bo M,  Capello D, et al. Molecular and clinical features of chronic
lymphocytic leukaemia with stereotyped B cell receptors: results from an Ital-
ian  multicentre study. Br J Haematol 2009;144(4):492–506.
24] Oscier D, Wade R, Davis Z, et al. Prognostic factors identiﬁed three risk groups
in  the LRF CLL4 trial, independent of treatment allocation. Haematol Hematol
J  2010;95(10):1705–12.
25] Wartenberg M,  Vasil P, zum Bueschenfelde CM,  et al. Somatic hypermutation
analysis in follicular lymphoma provides evidence suggesting bidirectional cell
migration between lymph node and bone marrow during disease progression
and relapse. Haematologica 2013;98(9):1433–41.
26] Bende RJ, Aarts WM,  Riedl RG, et al. Among B cell non-Hodgkin’s lymphomas,
MALT lymphomas express a unique antibody repertoire with frequent rheuma-
toid factor reactivity. J Exp Med  2005;201(8):1229–41.
27] Berget E, Helgeland L, Liseth K, et al. Prognostic value of bone marrow involve-
ment by clonal immunoglobulin gene rearrangements in follicular lymphoma.
J  Clin Pathol 2014;67(12):1072–7.
28] van Dongen JJM, Langerak AW,  Bruggemann M,  et al. Design and standard-
ization of PCR primers and protocols for detection of clonal immunoglobulin
and T-cell receptor gene recombinations in suspect lymphoproliferations:
report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia
2003;17(12):2257–317.
29] Berget E, Helgeland L, Molven A, et al. Detection of clonality in follicular lym-
phoma using formalin-ﬁxed, parafﬁn-embedded tissue samples and BIOMED-2
immunoglobulin primers. J Clin Pathol 2011;64(1):37–41.
30] Brezinschek HP, Foster SJ, Brezinschek RI, et al. Analysis of the human V-H
gene repertoire—differential effects of selection and somatic hypermutation
on human peripheral CD5(+)/IgM(+) and CD5(-)/IgM(+) B cells. J Clin Invest
1997;99(10):2488–501.
[
[arch 39 (2015) 702–708
31] Brezinschek HP, Brezinschek RI, Dorner T, et al. Similar characteristics of the
CDR3 of V(H)1-69/DP-10 rearrangements in normal human peripheral blood
and chronic lymphocytic leukaemia B cells. Br J Haematol 1998;102(2):516–21.
32] Catherwood MA, Gonzalez D, Patton C, et al. Improved clonality assessment
in  germinal centre/post-germinal centre non-Hodgkin’s lymphomas with high
rates of somatic hypermutation. J Clin Pathol 2007;60(5):524–8.
33] Rosenquist R, Lindstrom A, Holmberg D, et al. V-H gene family utilization in
different B cell lymphoma subgroups. Eur J Haematol 1999;62(2):123–8.
34] Bahler DW,  Levy R. Clonal evolution of a follicular lymphoma: evidence for
antigen selection. Proc Natl Acad Sci USA 1992;89(15):6770–4.
35] Stiernholm N, Kuzniar B, Berinstein NL. Absence of immunoglobulin variable
region hypermutation in a large cell lymphoma after in vivo and in vitro prop-
agation. Blood 1992;80(3):738–43.
36] Hsu FJ, Levy R. Preferential use of the VH4 Ig gene family by diffuse large-cell
lymphoma. Blood 1995;86(8):3072–82.
37] Delecluse HJ, Hummel M,  Maraﬁoti T, et al. Common and HIV-related diffuse
large B cell lymphomas differ in their immunoglobulin gene mutation pattern.
J  Pathol 1999;188(2):133–8.
38] Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin
genes in diffuse large B cell lymphomas. Blood 2000;95(5):1797–803.
39] Baptista MJ,  Calpe E, Fernandez E, et al. Analysis of the IGHV region in Burkitt’s
lymphomas supports a germinal centre origin and a role for superantigens in
lymphomagenesis. Leuk Res 2014;38(4):509–15.
40] Navarro A, Clot G, Royo C, et al. Molecular subsets of mantle cell lymphoma
deﬁned by the IGHV mutational status and SOX11 expression have distinct
biologic and clinical features. Cancer Res 2012;72(20):5307–16.
41] Kuppers R. Mechanisms of B cell lymphoma pathogenesis. Nat Rev Cancer
2005;5(4):251–62.
42] Zenz T, Mertens D, Kuppers R, et al. From pathogenesis to treatment of chronic
lymphocytic leukaemia. Nat Rev Cancer 2010;10(1):37–50.
